Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Treatment With the Combination of Vemurafenib, Cobimetinib and Atezolizumab in Limited Metastasis of Malignant Melanoma (AJCC Stage IIIC/IV) and Integrated Biomarker Study: a Single Armed, Two Cohort, Phase II EADO Trial NEO-VC

NCT02303951 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT02303951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02303951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Treatment With the Combination of Vemurafenib, Cobimetinib and Atezolizumab in Limited Metastasis of Malignant Melanoma (AJCC Stage IIIC/IV) and Integrated Biomarker Study: a Single Armed, Two Cohort, Phase II EADO Trial NEO-VC
Lead sponsor
University Hospital Tuebingen
Phase
Phase 2
Overall status
Terminated
Start date
January 22, 2015
Completion date
May 14, 2020
Enrollment
47 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma